Health
LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint – News-Medical.Net
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by…
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results…
-
General22 hours agoTrial of celebrity crocodile wrangler Matt Wright to hear from more witnesses
-
Noosa News19 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
General23 hours agoPM kicks off roundtable with call for lasting reform
-
Noosa News16 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032